Compare ACADIA Pharmaceuticals Inc. (ACAD) vs DoorDash Inc (DASH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs DoorDash Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.9 (market cap $4.49B), while DoorDash Inc trades at $187.94 (market cap $85.28B). The key difference: DoorDash Inc is far larger — about 19× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | DASH | |
|---|---|---|
Market Cap | $4.49B | $85.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $281.74 |
52-Week Low | $20.06 | $146.60 |
Enterprise Value | $3.69B | $83.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DoorDash (DASH) trades at $195.72, up 1.93% today, with a bullish technical signal and strong analyst consensus. Revenue grew to $13.72B in 2025, with net income reaching $935M, though recent quarters show mixed earnings performance. The stock is near resistance at $200, with RSI indicating overbought conditions. Recent news highlights AI initiatives and market dominance.
Outlook remains positive with a $231.50 consensus price target, but risks include competition and high valuation multiples. Earnings growth and international expansion are key catalysts, while inflation and execution challenges pose headwinds for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
